Literature DB >> 21318226

The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo.

Juyeon Jung1, Yeon Sung Son, Hongryeol Park, Seong Kook Jeon, Jung Whoi Lee, Song-Yi Choi, Jin-Man Kim, Young-Guen Kwon, Hyo Jeong Hong, Jeong-Ki Min.   

Abstract

Recent studies have demonstrated that the cell adhesion molecule, L1, is expressed in several malignant tumor types and its expression correlates with tumor progression and metastasis. However, the role of L1 in gallbladder carcinoma (GBC) remains unclear. Here, we demonstrate that L1 is expressed in GBC cells and plays an important role in the growth, motility, invasiveness, and adhesiveness of GBC cells. Specific depletion or overexpression of L1 in the GBC cell lines JCRB1033 and SNU-308, respectively, was achieved by lentivirus-mediated transduction and expression of an L1 mRNA-specific short hairpin RNA or full-length human L1. Stable depletion of L1 led to a significant decrease in GBC cell proliferation, migration and invasion, as well as decreased intracellular signaling through AKT and FAK. Overexpression of L1 in GBC cells enhanced these cellular activities. In a GBC xenograft nude mouse model, suppression of L1 markedly reduced tumor growth and increased the survival of tumor-bearing mice whereas L1 overexpression stimulated tumorigenicity. Taken together, these results suggest that L1 plays a crucial role in GBC progression and may be a novel therapeutic target in GBC treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21318226     DOI: 10.3892/or.2011.1181

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model.

Authors:  Eung Suk Lee; Mun Sik Jeong; Rohit Singh; Juyeon Jung; Hyunho Yoon; Jeong Ki Min; Kyung Hyun Kim; Hyo Jeong Hong
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

2.  L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer.

Authors:  Dong-liang Chen; Zhao-lei Zeng; Jing Yang; Chao Ren; De-shen Wang; Wen-jing Wu; Rui-hua Xu
Journal:  J Hematol Oncol       Date:  2013-06-27       Impact factor: 17.388

3.  TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

Authors:  Cai M Roberts; Michelle A Tran; Mary C Pitruzzello; Wei Wen; Joana Loeza; Thanh H Dellinger; Gil Mor; Carlotta A Glackin
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

4.  L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation.

Authors:  Haejung Kim; Haein Hwang; Hansoo Lee; Hyo Jeong Hong
Journal:  Mol Cells       Date:  2017-05-24       Impact factor: 5.034

5.  Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.

Authors:  Seulki Cho; Insoo Park; Haejung Kim; Mun Sik Jeong; Mooney Lim; Eung Suk Lee; Jin Hong Kim; Semi Kim; Hyo Jeong Hong
Journal:  MAbs       Date:  2016-01-19       Impact factor: 5.857

6.  Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.

Authors:  Seulki Cho; Tae Sup Lee; In Ho Song; A-Ram Kim; Yoon-Jin Lee; Haejung Kim; Haein Hwang; Mun Sik Jeong; Seung Goo Kang; Hyo Jeong Hong
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

7.  CHL1 suppresses tumor growth and metastasis in nasopharyngeal carcinoma by repressing PI3K/AKT signaling pathway via interaction with Integrin β1 and Merlin.

Authors:  Juan Chen; Chen Jiang; Li Fu; Cai-Lei Zhu; Yan-Qun Xiang; Ling-Xi Jiang; Qian Chen; Wai Man Liu; Jin-Na Chen; Li-Yi Zhang; Ming Liu; Chao Chen; Hong Tang; Bo Wang; Sai Wah Tsao; Dora Lai-Wan Kwong; Xin-Yuan Guan
Journal:  Int J Biol Sci       Date:  2019-07-11       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.